Accessibility Menu
Arch Biopartners logo

Arch Biopartners

(OTC) ACHFF

Current Price$0.42
Market Cap$23.78M
Since IPO (2011)-51%
5 Year-65%
1 Year-73%
1 Month+15%

Arch Biopartners Financials at a Glance

Market Cap

$23.78M

Revenue (TTM)

CA$158.08K

Net Income (TTM)

-CA$2.59M

EPS (TTM)

-$0.03

P/E Ratio

-12.41

Dividend

$0.00

Beta (Volatility)

0.45 (Low)

Price

$0.42

Volume

39,500

Open

$0.35

Previous Close

$0.35

Daily Range

$0.34 - $0.42

52-Week Range

$0.29 - $1.42

Estimated Earnings Date

Aug 27, 2026

ACHFF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Arch Biopartners

Industry

Life Sciences Tools and Services

CEO

Richard Gabriel Muruve, MBA

Headquarters

Toronto, ON M4T 2M5, CA

ACHFF Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

0%

Return on Capital

67%

Return on Assets

-6%

Earnings Yield

-8.06%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$23.78M

Shares Outstanding

67.93M

Volume

39.50K

Avg. Volume

26.21K

Financials (TTM)

Gross Profit

CA$0.00

Operating Income

-CA$1.50M

EBITDA

-CA$1.29M

Operating Cash Flow

-CA$1.59M

Capital Expenditure

CA$5.01

Free Cash Flow

-CA$1.59M

Cash & ST Invst.

CA$2.10K

Total Debt

CA$2.84M

Arch Biopartners Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

CA$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$23.78M

N/A

Market Cap/Employee

$3.96M

N/A

Employees

6

N/A

Net Income

-CA$522.35K

+16.3%

EBITDA

-CA$460.61K

-809.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$437.89K

+4266.3%

Total Debt

CA$2.74M

+14.9%

Accounts Receivable

CA$21.36K

-95.6%

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$2.74M

+14.9%

Return on Assets

-5.60%

N/A

Return on Invested Capital

66.73%

N/A

Free Cash Flow

-CA$89.34K

+84.5%

Operating Cash Flow

-CA$89.34K

+84.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OTLCOncotelic Therapeutics, Inc.
$0.05+11.11%
ZIVOZIVO Bioscience, Inc.
$3.69+0.00%
INNMFAmplia Therapeutics Limited
$0.08+0.00%
CVALFCovalon Technologies Ltd.
$1.54-0.65%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$15.94+0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$83.05+0.07%
SMCISuper Micro Computer
$30.33+0.09%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$36.73-0.07%

Questions About ACHFF

What is the current price of Arch Biopartners?

Arch Biopartners is trading at $0.42 per share.

What is the 52-week range for Arch Biopartners?

Over the past 52 weeks, Arch Biopartners has traded between $0.29 and $1.42.

How much debt does Arch Biopartners have?

As of the most recent reporting period, Arch Biopartners reported total debt of CA$1.96M.

How much cash does Arch Biopartners have on hand?

Arch Biopartners reported CA$312.97K in cash and cash equivalents in its most recent financial results.

What is Arch Biopartners’s dividend yield?

Arch Biopartners does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.